Wednesday, October 28, 2026
BTIG kept its Buy rating on Cullinan Therapeutics (CGEM) and raised its price target to $41 from $40.
Monday, October 19, 2026
BTIG kept its Buy rating on Cullinan Therapeutics (CGEM).
Friday, October 2, 2026
HC Wainwright & Co. kept its Buy rating on Cullinan Therapeutics (CGEM).
Friday, September 25, 2026
HC Wainwright & Co. kept its Buy rating on Cullinan Therapeutics (CGEM) and raised its price target to $35 from $30.
Monday, September 14, 2026
BTIG kept its Buy rating on Cullinan Therapeutics (CGEM) and raised its price target to $40 from $39.
Monday, August 17, 2026
HC Wainwright & Co. kept its Buy rating on Cullinan Therapeutics (CGEM).
Thursday, August 13, 2026
Wedbush kept its Outperform rating on Cullinan Therapeutics (CGEM) and raised its price target to $42 from $37.
Frequently asked questions
What is the latest news on CGEM?
Oct 28, 2026: BTIG kept its Buy rating on Cullinan Therapeutics (CGEM) and raised its price target to $41 from $40. (BTIG) · Oct 19, 2026: BTIG kept its Buy rating on Cullinan Therapeutics (CGEM). (BTIG) · Oct 2, 2026: HC Wainwright & Co. kept its Buy rating on Cullinan Therapeutics (CGEM). (HC Wainwright & Co.)
What are analysts saying about CGEM?
Oct 28, 2026: BTIG kept its Buy rating on Cullinan Therapeutics (CGEM) and raised its price target to $41 from $40. · Oct 19, 2026: BTIG kept its Buy rating on Cullinan Therapeutics (CGEM). · Oct 2, 2026: HC Wainwright & Co. kept its Buy rating on Cullinan Therapeutics (CGEM).
Get CGEM news as it happens
Every headline, SEC filing and analyst action for CGEM on your live chart, with important news marked and alerts when it matters.
Try SEPT Free